Alpha-emitting radium-223: Two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer

S. Nilsson1, L. Franzén2, C. Parker3, B. Bolstad4, T. Ramdahl4, M. Thuresson5 and Ø.S. Bruland6

1Karolinska University Hospital, Stockholm, Sweden; 2Sundsvall Hospital, Sundsvall, Sweden; 3Royal Marsden Hospital, Sutton, UK; 4Algeta ASA, Oslo, Norway; 5Statisticon AB, Uppsala, Sweden; 6University of Oslo and The Radium Hospital, Oslo, Norway

BACKGROUND

The bone-seeking pharmaceutical Alpharadin® (223 RaCl₂) is under clinical development as a novel treatment for patients with skeletal metastases. Clinical studies have shown that toxicity is low, repeated dosing is feasible and seems to improve overall survival (1,2). A pivotal phase-3 trial in patients with hormone refractory prostate cancer (HRPC) is currently recruiting.

METHODS AND TRIAL DESIGN

In a randomized phase 2 trial 64 HRPC patients with painful bone metastases received 4 monthly injections of Alpharadin or placebo as an adjuvant to external beam radiotherapy (EBRT). A 4.5 months difference in survival was observed at 18 months follow up (2). Here we report 24 months follow up data on survival, long term toxicity, sub-group analyses based on disease status at inclusion and pre-treatment EBRT.

MAIN ELIGIBILITY CRITERIA

• Confirmed hormone refractory prostate cancer with painful skeletal metastases
• Referred to palliative external radiotherapy for skeletal metastases
• No other currently active malignancy or known metastases to other organ than skeleton

RESULTS

TWO YEAR SURVIVAL

At 24 months, ten patients (30%) that received Alpharadin were alive and four (13%) in the placebo-group. Median survival was 65 weeks compared with 46 weeks, respectively (ITT). Hazard ratio adjusted for baseline covariates was 2.10 (95% CI; 1.14-3.88; p=0.017, Cox regression).

OTHER SIGNIFICANT FINDINGS

In a composite analysis of patients with Hb >110 g/dl, bone-ALP <800 ng/ml, and PSA <1,000 ng/ml the median survival was 102 versus 49 weeks in the two groups (p= 0.029, Log-rank). Patients with body mass index above 23.0 (27 patients in Alpharadin and 25 in placebo) had a median survival of 102 and 54 weeks, respectively (p=0.035, Log-rank). The administered EBRT at baseline was comparable between the two groups with no difference in the use of single dose versus fractionated EBRT.

NO LONG TERM TOXICITY

No long term haematological toxicity or any cases of leukaemia, myelodysplastic syndrome, aplastic anaemia or bone sarcoma were reported.

CONCLUSION

The therapeutic benefit seems to be greater for more fit patients than for those with extensive skeletal involvement. However, the relative improvement in survival was maintained irrespective of extent of disease at baseline. A benign side effect profile was documented following repeated Alpharadin treatment.

REFERENCES

1) Nilsson S et al., Clin Cancer Res. 2005;11 (12): 4451-4459